publication venue for
- S318 Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP. 116:s138-s138. 2021
- American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.. 109 Suppl 1:S2-26.
- An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. 104:s8-s35.
- An evidence-based position statement on the management of irritable bowel syndrome.. 104 Suppl 1:S1-35.
- Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.. 103:815-819.
- Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis.. 109:1350-1365.
- Efficacy of Antispasmodics and Peppermint Oil in Irritable Bowel Syndrome. 103:s459-s460.
- Efficacy of Fiber in Irritable Bowel Syndrome. 103:s459-S459.
- Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis.. 109:1547-1561.
- Evaluation of chronic diarrhea and irritable bowel syndrome with diarrhea in adults in the era of precision medicine.. 113:660-669.
- Multisociety Sedation Curriculum for Gastrointestinal Endoscopy.
- Neurotrophin-3 improves functional constipation.. 98:1338-1347.
- Response to: The Significance of Mast Cell Activation in The Era of Precision Medicine.. 113:1726-1726.
- Systematic Review on the Management of Chronic Constipation in North America. 100:s5-s22.
- Systematic review on the management of chronic constipation in North America.. 100 Suppl 1:S5-S21.
- The core curriculum in gastroenterology: training the gastroenterologists of the future.. 102:919-920.
- The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis.. 109:1367-1374.
- Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP 2021
- Growth Hormone Normalizes Gastrointestinal Symptoms in mTBI Patients 2020